Loading clinical trials...
Loading clinical trials...
A study to determine the accuracy of FLT-PET in quantifying tumor cell proliferation at the initial staging of patients with Non-Hodgkin's Lymphoma in comparison wit the "gold standard" FDG-PET.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of Oklahoma
Collaborators
NCT00131014 · Non-Hodgkin's Lymphoma, Hodgkin's Disease, and more
NCT05735717 · Hematologic Malignancy, Acute Leukemia, and more
NCT06667687 · Non-Hodgkin's Lymphoma
NCT04664179 · EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, and more
NCT07239323 · B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, and more
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions